Living with Pompe disease means becoming familiar with a set of tests and numbers that most people will never encounter. Over time, these results become a kind of second language, helping you and your care team track how your disease is progressing, how well your treatment is working, and when something needs attention.
But test results can also be confusing, especially when values fluctuate or when no one has taken the time to explain what they mean. Knowing what each test is measuring, what range is typical, and what a change in results might signal can help you participate more actively in your own care and ask better questions at appointments.
This guide covers the most common tests used to monitor Pompe disease: what they measure, why they matter, and how to make sense of what you’re seeing on your lab reports.
A quick note: This guide is here to help you understand the tests you may come across and make sense of your own reports. It isn’t medical advice, and it can’t replace your care team’s interpretation of your specific results.
—
Why Monitoring Matters in Pompe Disease
Pompe disease is progressive, which means the muscle damage it causes tends to worsen over time. The pace of that progression varies widely from person to person, and it can be difficult to notice gradual changes from one appointment to the next. Regular testing gives your care team objective data points that go beyond how you feel on any given day.
Monitoring serves several purposes:
- Tracking disease progression: identifying changes in muscle strength, respiratory function, or organ health before symptoms become severe
- Evaluating treatment response: determining whether enzyme replacement therapy (ERT) or other interventions are having the expected effect
- Catching complications early: some aspects of Pompe disease, like cardiac involvement or respiratory decline, can develop quietly
- Establishing your personal baseline: what’s normal for you is often more meaningful than a population average
Not every result on a lab report carries the same weight. Understanding which numbers your team is watching most closely, and why, helps put everything in context.
—
Pulmonary Function Tests (PFTs)
Respiratory complications are among the most serious consequences of Pompe disease, and pulmonary function tests are one of the most important tools for tracking them. These tests measure how well your lungs are working (specifically, how much air you can move in and out, and how efficiently).
What’s being measured:
- FVC (Forced Vital Capacity): the total volume of air you can forcefully exhale after taking the deepest breath possible. This is the single most watched number in Pompe disease. A declining FVC can indicate that the respiratory muscles are weakening.
- FEV1 (Forced Expiratory Volume in 1 second): how much of your FVC you can exhale in the first second. This helps distinguish between different types of breathing difficulty.
- MIP and MEP (Maximal Inspiratory and Expiratory Pressure): these measure the strength of your breathing muscles directly, rather than the volume of air moved.
- Upright vs. supine FVC: some clinics will measure your FVC both sitting upright and lying flat. A significant drop in FVC when lying down (more than 10–20%) can indicate diaphragm weakness, which is particularly relevant in Pompe disease.
What the numbers mean:
Results are typically expressed as a percentage of what would be predicted for someone of your age, height, and sex. A value of 80% or above is generally considered within normal range. In Pompe disease, the trend over time matters more than any single measurement — a gradual decline is a signal worth discussing with your respirologist, even if individual values still fall within an acceptable range.
How often:
PFTs are typically done every six to twelve months, or more frequently if there are concerns about respiratory decline.
—
Sleep Studies and Overnight Breathing Monitoring
Daytime pulmonary function tests capture how your lungs work while you’re awake and upright. However, in Pompe disease, some of the earliest signs of respiratory muscle weakness appear during sleep. When you lie down and move into deeper sleep, the diaphragm does more of the work of breathing, and a weakening diaphragm may struggle to keep up. This can lead to shallow breathing overnight (nocturnal hypoventilation) before it’s noticeable during the day.
What’s being measured:
- Overnight pulse oximetry: tracks blood oxygen levels through the night, flagging dips that suggest breathing is less effective during sleep.
- Capnography (transcutaneous or end-tidal CO₂): measures carbon dioxide levels. A rise in CO₂ overnight is one of the earliest signs of hypoventilation, sometimes appearing before oxygen levels fall.
- Polysomnography (a full sleep study): a more comprehensive overnight assessment used when sleep-disordered breathing is suspected, recording breathing patterns, oxygen and CO₂, heart rate, and sleep stages together.
Signs that might prompt these tests:
Morning headaches, un-refreshing sleep, daytime fatigue or sleepiness, or shortness of breath when lying flat can all point toward overnight breathing changes. These are worth mentioning to your care team even if your daytime PFTs look stable.
Why this matters:
Catching nocturnal hypoventilation early opens the door to supportive measures such as non-invasive ventilation, for example a BiPAP machine used at night, before daytime breathing is significantly affected.
How often:
This varies. Overnight monitoring may be added when symptoms suggest it, when PFTs decline, or as part of periodic review with a respirologist.
—
Creatine Kinase (CK)
CK is an enzyme found primarily in muscle tissue. When muscle cells are damaged or break down, CK leaks into the bloodstream. This means elevated CK levels in a blood test can indicate ongoing muscle damage.
What it tells us:
In Pompe disease, CK is often elevated, particularly in the classic infantile form and in people who were diagnosed later in life and had significant muscle involvement before starting treatment. It’s a general marker of muscle stress, not a precise measure of Pompe-specific activity.
CK levels can be influenced by many things beyond Pompe disease: strenuous exercise, other muscle conditions, certain medications, and even ethnicity (baseline CK levels vary across populations). This means a high CK reading is not automatically cause for alarm, especially if it’s been elevated consistently and your other markers are stable.
What you might see on your report:
Normal CK ranges vary between labs, but a general reference range for adults is roughly 30–200 U/L. In Pompe disease, levels may run significantly higher. What your team is watching for is change (e.g., a CK that was previously stable and suddenly rises may warrant investigation).
—
Liver Enzymes: ALT and AST
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are enzymes often associated with liver health, but they’re also present in muscle tissue. In Pompe disease, elevated ALT and AST can reflect muscle breakdown rather than liver problem. This distinction is important to understand, particularly in newly diagnosed patients.
Why this matters:
Some people with Pompe disease, especially those diagnosed as children, first come to medical attention because routine bloodwork showed elevated liver enzymes. When ALT and AST are elevated and CK is also elevated, it often points to a muscle source rather than the liver. Your care team may order additional tests to clarify the source.
During ERT:
Liver enzyme levels are sometimes monitored during enzyme replacement therapy to watch for any treatment-related effects. Isolated, mild elevations are common and often not clinically significant but patterns or larger increases may prompt further evaluation.
—
Glucose Tetrasaccharide (Hex4) — Urine Biomarker
Hex4, or GlcNAc, is a biomarker that can be measured in urine. It reflects the amount of glycogen being broken down abnormally in the body, which is directly related to the underlying problem in Pompe disease.
What it tells us:
Elevated Hex4 in urine is one of the more specific biomarkers for Pompe disease. In people who are on ERT, Hex4 levels often decrease after treatment begins, which can serve as an indicator that the therapy is having an effect at the cellular level. Rising Hex4 levels might suggest that disease activity is increasing or that treatment response is declining.
Limitations:
Hex4 is a research and monitoring tool, not a complete picture on its own. It’s used alongside other tests, and its role in routine clinical monitoring is still evolving. Not all clinics measure it routinely, but it’s worth asking your metabolic specialist whether it’s part of your monitoring plan.
—
Antibody Testing (Anti-rhGAA Antibodies)
For people whose care includes enzyme replacement therapy, the treatment works by supplying a recombinant (laboratory-made) version of the GAA enzyme the body doesn’t produce enough of on its own. For some people, the immune system recognizes this infused enzyme as foreign and makes antibodies against it. A blood test can measure the level, or titer, of these antibodies.
Why this matters:
Antibodies to the infused enzyme can, in some cases, reduce how well treatment works by interfering with the enzyme before it reaches the cells that need it. High or sustained antibody levels are also occasionally linked to infusion-associated reactions. Many people never develop meaningful levels, and many who do still respond well, but it’s one factor a care team may weigh when trying to understand an unexpected change.
When it’s checked:
Antibody testing isn’t part of everyone’s routine bloodwork. It’s most likely to come up early in treatment, or when there’s a reason to look more closely, such as an infusion reaction, or a decline in other measures like FVC or six-minute walk distance that isn’t otherwise explained. If an infusion schedule isn’t part of your care, this test won’t apply to you.
—
Echocardiogram (Echo)
An echocardiogram uses ultrasound to create images of the heart, allowing your care team to assess its size, structure, and function. Cardiac involvement is particularly significant in the classic infantile form of Pompe disease, where cardiomegaly (enlargement of the heart) and hypertrophic cardiomyopathy (thickening of the heart muscle) are common and can be life-threatening without treatment.
What’s being measured:
- Left ventricular mass: whether the heart muscle is thickened
- Ejection fraction: how effectively the heart is pumping blood
- Overall structure and function: looking for abnormalities in the valves and chambers
In late-onset Pompe disease:
Significant cardiac involvement is less common in late-onset Pompe disease, but some degree of cardiac monitoring is still part of standard care. Your cardiologist can advise on the appropriate frequency of echocardiograms based on your specific situation.
What to ask:
If cardiac findings are part of your history, it’s worth asking your care team what they’re watching for on each follow-up echo, and what thresholds would prompt a change in your care.
—
Electrocardiogram (ECG)
While an echocardiogram shows the structure and pumping of the heart, an electrocardiogram (ECG) records its electrical activity, the signals that coordinate each heartbeat. The two tests answer different questions, which is why both can be part of cardiac monitoring.
What it can show:
An ECG can detect abnormalities in heart rhythm and in the electrical conduction system. In the classic infantile form of Pompe disease, where the heart muscle is often thickened, ECGs frequently show characteristic patterns (such as a short PR interval and unusually high electrical voltages) and can pick up rhythm disturbances that need attention.
In late-onset Pompe disease:
As with echocardiograms, significant cardiac involvement is less common in late-onset disease. An ECG is quick and non-invasive, and whether it’s included, and how often, depends on your individual history and your cardiologist’s judgment.
What to ask:
If ECGs are part of your monitoring, it’s reasonable to ask what your care team is looking for, and whether any findings would change your follow-up.
—
Muscle Function and Strength Testing
Not all monitoring takes the form of blood or urine tests. Standardized physical assessments are a central part of Pompe disease monitoring and provide a direct measure of functional muscle strength.
Common assessments include:
- 6-Minute Walk Test (6MWT): measures how far you can walk in six minutes at a comfortable pace. Distance and changes over time reflect lower limb strength and endurance.
- Quick Motor Function Test (QMFT) or Pompe-specific motor scales: structured assessments of specific muscle groups and functional movements (rising from a chair, climbing stairs, etc.)
- Grip strength dynamometry: a standardized measure of hand and forearm strength
- Manual muscle testing (MRC scale): during a physical exam, a clinician grades the strength of individual muscle groups by having you push or resist against them. The most widely used system is the Medical Research Council (MRC) scale, which runs from 0 to 5 — 0 means no muscle contraction at all, 3 means the muscle can move against gravity but not against added resistance, and 5 means normal strength. Grading specific muscles this way lets your team track subtle changes in particular areas and compare them from one appointment to the next.
- Timed tests (such as time to walk 10 metres or time to rise from the floor): used to track changes in specific functional abilities
Why these matter:
Functional assessments capture what imaging and blood work cannot: how muscle weakness actually affects your daily life and independence. A stable CK alongside a declining 6-minute walk distance tells a different story than when both are declining together. Your physiotherapist or metabolic specialist will typically conduct these at regular intervals and compare them over time.
—
Muscle MRI
Magnetic resonance imaging (MRI) can look directly at muscle tissue, without radiation or anything invasive. In Pompe disease, MRI is increasingly used to see how muscles are affected and to track changes over time.
What it can show:
- Fatty replacement: healthy tissue is gradually replaced by fat as muscles are damaged. MRI can reveal the pattern and extent of this, sometimes in muscles before weakness is obvious on functional testing.
- Active change or inflammation: some MRI techniques can highlight muscle that appears to be undergoing more active change, which may help explain symptoms.
Why this matters:
Because MRI detects structural change non-invasively, it can complement functional tests and blood work, offering a picture of what’s happening inside specific muscle groups. Repeated over time, it can help show whether the disease is stable or progressing in areas that matter for movement.
A note on availability:
Muscle MRI isn’t yet a routine part of monitoring at every clinic, and the specific techniques vary. Whether it’s useful in your situation is worth discussing with a metabolic specialist or neurologist.
—
Swallowing and Bulbar Function
Pompe disease can affect the muscles involved in speaking and swallowing, sometimes called the bulbar muscles, though this varies a great deal from person to person. When these muscles are affected, it can lead to difficulty swallowing (dysphagia) or changes in speech, and swallowing difficulty carries a risk of food or liquid entering the airway.
How it’s assessed:
- A clinical swallowing evaluation by a speech-language pathologist, who observes swallowing and checks for signs of difficulty.
- Instrumented studies when needed, such as a videofluoroscopic swallow study (a moving X-ray of swallowing) or a fibreoptic endoscopic evaluation, which allow a closer look at what happens as you swallow.
- Assessment of speech and oromotor (mouth and tongue) function.
When it comes up:
These assessments are usually considered when there are symptoms to investigate: coughing or choking while eating or drinking, food feeling stuck, unexplained weight loss, or changes in the voice. If you’ve noticed anything like this, it’s worth raising, since swallowing safety is both manageable and important to stay ahead of.
—
Patient-Reported Outcomes and Quality-of-Life Measures
Not all monitoring comes from a machine or a lab. Some of the most important information comes directly from you, captured through structured questionnaires known as patient-reported outcome measures. These tools turn your own experience of living with Pompe disease into data that can be tracked over time.
What they capture:
- Everyday function: tools like the R-PAct scale, a Pompe-specific questionnaire, focus on how the disease affects daily activities and independence.
- Fatigue: instruments such as the Fatigue Severity Scale measure how much fatigue affects your life, since fatigue is a common and sometimes under-recognized part of the condition.
- Pain and overall quality of life: broader questionnaires capture aspects of wellbeing that other tests don’t reach.
Why these matter:
Objective tests and questionnaires answer different questions. Your FVC or six-minute walk distance can look stable while your fatigue or day-to-day function is changing, or the reverse. Completing these measures consistently gives your care team a fuller picture, and gives your lived experience a formal place in the record alongside the numbers.
—
Putting It All Together
No single test tells the whole story in Pompe disease. Your care team is looking at a combination of results — respiratory function, muscle biomarkers, cardiac health, physical performance, and how you’re feeling day to day — and interpreting them in context.
A few things to keep in mind when reviewing your results:
- Trends matter more than individual values. A result that’s slightly outside the normal range but has been stable for years is often less concerning than one that’s changing rapidly.
- Your baseline is your reference point. What’s normal for the general population may not reflect what’s normal for you. Ask your care team what your personal baseline looks like and what changes would concern them.
- Results don’t always align with symptoms. You may feel worse on a day when your numbers look acceptable, or vice versa. Both matter, and both are worth reporting.
- Ask for copies of your results. You have the right to your own medical records. Keeping a personal file of your test results over time allows you to track trends yourself and brings important context to appointments with new providers.
—
Questions Worth Asking at Your Next Appointment
If you’re not sure how to start a conversation about your monitoring results, these questions can help:
- Which of my current results are you most focused on, and why?
- How do my recent results compare to where I was six months or a year ago?
- Is there anything in my results that suggests a change in my treatment plan?
- Are there any tests we should add to my monitoring routine, or any we no longer need?
- What would you want to see happen before you considered adjusting my ERT dose or schedule?
—
A Word on Variability
Pompe disease monitoring can sometimes produce results that are puzzling, inconsistent, or hard to interpret, even for experienced clinicians. Not all tests are standardized across centres. Reference ranges vary between labs. Some biomarkers are still being studied. And individual variation in how the disease presents means that what’s significant for one person may be unremarkable for another.
If a result concerns you and your provider hasn’t flagged it, ask. Tell your clinician if you feel your test results are not reflective of how you’re feeling. Your lived experience is a form of data too, and the most useful monitoring happens when providers and patients are looking at the full picture together.
If you’d like help understanding a specific test result or preparing questions for an upcoming appointment, consider reaching out to your metabolic specialist. The Canadian Association of Pompe is also available to help you find resources and connect with others.